Article
Ruboxistaurin results: Eli Lilly plans more trials
Indianapolis-Eli Lilly and Co. will delay the submission of its ruboxistaurin for the treatment of diabetic retinopathy and diabetic macular edema (DME) after two clinical trials failed to achieve satisfactory results on disease progression.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
